| INTRODUCTION
The Fontan procedure is the current palliation for patients with single ventricle physiology unable to undergo biventricular repair for a range of congenital heart diseases. 1 The principle underlying the Fontan procedure implies the presence of 2 vascular resistances in sequence, namely systemic and pulmonary. As the pulmonary circuit has no pump, hypertension in the systemic veins acts to overcome pulmonary vascular resistance (PVR). As a consequence, systemic vein pressure is dependent on 3 factors: the energy lost between the systemic veins and the small pulmonary arteries (the Fontan circuit anatomy), the energy lost in the lung capillaries, and the energy lost between the pulmonary veins and the ventricle, including diastolic dysfunction or atrioventricular valve anomalies. The characteristics of the pulmonary vasculature in patients with single ventricle physiology are certainly some of the most important limitations for the Fontan procedure, and maintaining low PVR and low ventricular filling pressure is essential to guarantee the long-term durability of the Fontan circuit. 2 The bidirectional cavopulmonary shunt, also known as the bidirectional Glenn shunt, has become an important staging procedure for the Fontan-type operation. 3 Preoperative ventricular function and preoperative pulmonary artery pressure are the essential elements of a successful Fontan circulation. 2 Previous studies have demonstrated that the absence of a pulsatile pulmonary flow induces endothelial dysfunction with impaired pulmonary vasodilation. [3] [4] [5] [6] On the contrary, capillary recruitment is promoted by pulsatile perfusion, thereby increasing the cross-sectional area of the vascular bed, lowering resistance, and increasing the gas exchange surface area. 7 The endothelial dysfunction associated with the absence of pulsatile flow may have a role in increasing PVR and may be an important element in the failing Fontan circulation. Furthermore, long-term pulmonary vasculature remodeling after Fontan surgery has been shown to be responsible for the increase in pulmonary resistance in patients who died during follow-up. 8 Therefore, keeping PVR low is mandatory both before and after Fontan completion, suggesting a potential role for pulmonary vasodilators in these patients. [9] [10] [11] [12] Small nonrandomized studies have reported conflicting data on the efficacy of pulmonary vasodilators in Fontan patients, 13,14 both on functional capacity improvement and on relief of protein-losing enteropathy (PLE). Of note, most of these studies did not use heart catheterization to monitor the patients' hemodynamic status. Few studies have evaluated the utility of new pulmonary vasodilators in patients with single ventricle physiology before Fontan completion. Therefore, the aim of this retrospective study was to investigate the potential effect of pulmonary vasodilators on the pulmonary vasculature in Fontan patients.
| MATERIALS AND METHODS

| Study population
This was a retrospective, nonrandomized, single-center study conducted in University of Padova between January and December 2015.
Patients with univentricular physiology medically treated with pulmonary vasodilators were enrolled in the study. 
| Hemodynamic data
Data from 2 different right heart catheterizations (RHCs) were collected. In Groups A and B, examinations were performed before starting treatment (baseline) and 6-24 months later. All patients were in the same stage palliation at both the first catheterization and second catheterization. The RHCs were performed under deep sedation, with assisted ventilation using a laryngeal mask. Cardiac output was calculated using the Fick principle. The following data were collected for 
| Safety
All patients received a clinical evaluation before treatment, after 1 month, and immediately prior to the second catheterization. Serum aminotransferase and blood cell counts were assessed 15 days after treatment, after 1, 2, and 3 months, and every 3 months thereafter.
Adverse events were recorded. 
| Statistical analysis
| RESULTS
| Patient characteristics
In total, 27 patients were enrolled in the study. Nine of these patients initiated vasodilator therapy after Glenn procedure or just after the Tables 1 and 2 . Mean age ± SD was 3.2 ± 1.5 years (Group A), 26.8 ± 12.7 years (Group B), and 3.1 ± 1.0 years (Group C).
In Group A, 6 patients commenced treatment with a pulmonary vasodilator after Glenn procedure and 3 patients just after Fontan completion. All patients received bosentan 2 mg/kg twice daily. Pulmonary vasodilators were indicated due to high mPAP (n = 2); high mPAP and high PVR (n = 3); high PVR (n = 1); plastic bronchitis (n = 2); and PLE and persistent pleural effusion (n = 1). In Group B, 9 patients started pulmonary vasodilators >5 years after Fontan completion, 7 patients were prescribed bosentan 125 mg twice daily, one was prescribed ambrisentan 5 mg daily, and one was prescribed sildenafil 20 mg 3 times daily. Pulmonary vasodilators were indicated for high PVR (n = 1); high PVR and high mPAP (n = 2); PLE (n = 4); PLE and high PVR (n = 2).
In Group C (control), the mean time between the 2 catheterizations was 17.8 ± 11.2 months. All patients in Group C were in the pre- 
| Hemodynamic outcomes
Hemodynamic outcomes in patients treated with vasodilators (pooled for Groups A and B) are shown in Table 3 . Pulmonary flow (P = .04), PVR (P < .001), RPA and LPA diameters (P < .001), PAC (P = .004), and the Nakata index (P = .001) improved significantly between the 2 RHCs. Similar results were seen in each group when analyzed separately (Group A: Table 4 ; Group B: Table 5 ). Differences between Groups A and C are shown in *mm Hg]; P = .03) than those in Group C. There was also a trend for higher mPAP. At 1 year, PCW decreased significantly in the Group C (P = .046) but remained relatively high in Group A. However, the arteriolar gradient (Group A-24 ± 2'% vs Group C + 8 ± 35%; P = .03) and PVR (Group A −32 ± 15% vs Group C + 2 ± 40%, P = .04) decreased significantly in Group A but not in Group C. In addition, increases in pulmonary artery diameter and PAC were only detected in Group A (Nakata index: Group A + 26 ± 24% vs Group C-8 ± 17%, P = .003; PAC: Group A + 80 ± 49% vs Group C-5 ± 30%, P = .001).
We found similar results excluding the 3 patients that already 
| Interventions
During the follow-up period, 9 of the 18 patients who received vasodilators (5 from Group A and 4 from Group B) were treated with percutaneous interventions (Table 1) : LPA angioplasty (n = 1); LPA stenting (n = 3); right ventricle-pulmonary artery (RV-PA) conduit stenting (n = 1); PA angioplasty (n = 1), extracardiac conduit stenting (n = 2); Glenn anastomosis angioplasty (n = 1); fistula occlusion (n = 2);
and atrioseptectomy (n = 1). Half of the patients in Group C (n = 5) underwent percutaneous interventions (Table 2) : LPA angioplasty (n = 2); LPA stenting (n = 1); LPA angioplasty and BT shunt obliteration (n = 1); and mammalian artery occlusion (n = 1). One patient had ventricle resynchronization due to pacemaker dysfunction.
| Surgical and clinical outcomes
In the subgroup of patients in Group A who started treatment after the Glenn procedure, 5 patients completed Fontan intervention successfully, while 1 patient was still on the waiting list for the final operation at the end of the study. The 2 patients with plastic bronchitis and the patient with PLE and persistent pleural effusion recovered. In Group B, 3 patients received heart transplant for persistent PLE and 1 patient died of malignant arrhythmia after the second catheterization.
At the end of the study, 1 patient was on the waiting list for heart transplant for persistent PLE and 1 patient had a PLE resolution. One patient had ascites resolution and PVR normalization, and 2 patients had hemodynamic improvement with PVR and mPAP normalization.
| Safety
One patient had a nonsignificant reduction in hemoglobin levels, and PuB, pulmonary band; BT, Blalock-Taussig; PDA, patent ductus arteriosus; BSA, body surface area; BG, bidirectional Glenn; RV, right ventricle; PA, pulmonary artery; PFO, patent foramen ovale; mPAP, mean pulmonary artery pressure; PVR, pulmonary vascular resistance; TAPVC, total anomalous pulmonary venous connection; HLHS, hypoplastic left heart syndrome; PB, plastic bronchitis; LPA, left pulmonary artery;
CAVC, complete atrioventricular canal defect; TCPC, total cavopulmonary connection; PLE, protein-losing enteropathy; DORV, double outlet right ventricle; PA/IVS, pulmonary atresia with intact ventricular septum; LT: lateral tunnel; TA, tricuspid atresia; HTx, heart transplant; LT, lateral tunnel; PCW, pulmonary capillary wedge pressure. 
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PuB, pulmonary band; BT, Blalock-Taussig; BSA, body surface area; TA, tricuspid atresia; BG, bidirectional Glenn; HD, hemodynamic; PDA, patent ductus arteriosus; LPA, left pulmonary artery; HLHS, hypoplastic left heart syndrome; RPA, right pulmonary artery; PA/IVS, pulmonary atresia with intact ventricular septum.
| DISCUSSION
Our study demonstrated that hemodynamic and anatomical data may improved symptoms and quality of life; however, the hemodynamic effect was higher in patients with lower pulmonary vascular compliance. Both diastolic function and venous compliance should be verified before starting therapy for cost and/or prognostic reasons. In our study, the 3 patients with the least favorable clinical outcome (heart transplantation in 2 patients and death in another) had a significant increase in PCW after starting therapy.
Pulmonary vasodilators were successfully proposed as treatment of Fontan failure based on laboratory parameters, New York Heart Association (NYHA) functional class worsening, appearance of symptoms (PLE, plastic bronchitis, ascites, etc.), or as a bridge to transplantation. 13, 14, 16 However, Fontan failure is a late event, while Fontan worsening is a slow process involving multiple variables. A tendency for Fontan patients to downgrade NYHA functional class due to selflimitation of daily activities was described. 17 Therefore, pulmonary vasodilators may have a role in the treatment of Fontan patients; however, the decision of when to initiate therapy and the indication for treatment should be assessed using hemodynamic data to maximize the effect of the therapy and to optimize the likelihood of Fontan survival.
Historically, pulmonary artery size and PVR were considered the most important parameters to measure in candidates for Fontan com- of Shuurring et al, 16 bosentan had no effect on the clinical status of .100
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BSA, body surface area; mPAP, mean pulmonary arterial pressure; dP, transpulmonary pressure gradient PAP, pulmonary artery pressure; PCW, pulmonary capillary wedge pressure; PBF, pulmonary blood flow; CO, cardiac output; PVR, pulmonary vascular resistance; PAC, pulmonary arterial compliance; RPA, right pulmonary artery; LPA, left pulmonary artery; cath, catheterization.
with a low prevalence of pacemaker implantation (3%), lower NYHA functional class (class I: 62% vs 28%), and lower prevalence of atriopulmonary Fontan (11%). Both studies reported a beneficial effect of bosentan in some patients; however, no prediction could be made of the midterm effect of bosentan in those patients.
| LIMITATIONS
This study has a number of limitations. The sample size was small due to the rarity of the disease and to the small number of patients currently treated with pulmonary vasodilators. In addition, Fontan patients are highly variable in terms of heart disease, clinical history, number and type of surgical interventions. Each of these variables may affect the clinical status of these patients. Furthermore, we recognize that growth and intervention on pulmonary arteries (angioplasty or stent implantation)
are a potential source of bias in our analysis. However, finding a group of Fontan patients completely "pure" from an intervention point of view is extremely rare. The rationale to have a group of control (Group C), having a comparable age (therefore spontaneous growth of pulmonary arteries with age) and a similar prevalence and type of intervention on pulmonary arteries, was to try to demonstrate that the further growth in pulmonary arteries' diameter and decrease in PVR observed in Group A may be attributed to the effect of pulmonary vasodilators.
Finally, enrollment was not randomized and some patients were catheterized as an intervention, while others were catheterized for diagnostic purposes. However, this lack of randomization did not affect our aim of investigating the impact of the use of pulmonary vasodilators on mPAP, PVR, Nakata index, and vascular compliance.
| CONCLUSIONS
Pulmonary vasodilators reduce pulmonary artery resistance and increase vascular compliance, pulmonary artery diameter, and cardiac output in Fontan patients. Pulmonary vasodilators can be used before
Fontan completion in patients at high risk of Fontan failure.
The greatest effect was seen in patients with higher pulmonary arteriolar gradient and lower PAC. In patients with low arteriolar gradient and high wedge pressure, the treatment increased both cardiac output and wedge pressure. For these reasons, in addition to the high costs of treatment, we suggest performing RHC before starting therapy with pulmonary vasodilators.
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